GH RESEARCH PLC (GHRS) Stock News
NASDAQ:GHRS - Nasdaq - IE000GID8VI0 - Common Stock - Currency: USD
GHRS Latest News, Press Relases and Analysis
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives...
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track...
What Makes GH Research (GHRS) a New Buy Stock
GH Research (GHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension...
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week
These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.
GH Research Announces Pricing of $150 Million Public Offering
DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives...
GH Research Announces Pricing of $150 Million Public Offering
GH Research Announces Proposed Public Offering
GH Research Announces Proposed Public Offering
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the...
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day...
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the...
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of...